Global Radiopharmaceuticals Industry

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Radiopharmaceuticals Industry
http://www.reportlinker.com/p01591554/Global-Radiopharmaceuticals-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America.

Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 69 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics, Inc., Cardinal Health, Inc., Covidien Plc, Eli Lilly and Company, Erigal Limited, EUSA Pharma (Europe) Ltd., GE Healthcare, IBA Group, Immunomedics, Inc., Jubilant Life Sciences Limited, Lantheus Medical Imaging Inc., Medi-Radiopharma Ltd., Nordion Inc., Peregrine Pharmaceuticals, Inc., PETNET Solutions Inc., Positron Corporation, Singapore Radiopharmaceuticals Pte Ltd., and Triad Isotopes, Inc.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Diagnostic Radiopharmaceuticals I-3
B. Therapeutic Radiopharmaceuticals I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Quick Primer II-1
Market Scenario: Recession and the Road Ahead II-1
Recession: A Period of Global Decline II-1
The Road to Recovery II-2
Outlook II-2
Impact of Healthcare Budget Cuts in Developed Economies: A Review II-3
Diagnostic Radiopharmaceuticals: The Dominant Segment II-4
Promising Developments in Therapeutic Radiopharmaceuticals
Underway II-4

2. GROWTH DRIVERS & TRENDS II-6
New Therapeutic Radiopharmaceuticals to Drive Global Market II-6
Improvements in Imaging Technology II-6
Rise in International Investments for Radiopharmaceuticals II-6
Bayer Algeta Partnership for Alpharadin II-6
Lutathera II-7
AREVA Med II-7
AtlabPharma and Cornell Well Medical Center II-7
Zevalin's Landmark FDA Approval Offers New Opportunities II-7
Improved Reimbursement for Therapeutic Radiopharmaceuticals II-7
Rise in Cancer Incidences & Access to Modern Therapeutics
Foster Growth II-8
World Cancer Statistics - Incidence and Mortality Data II-9
Table 1: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported in
Thousands for Asia-Oceania, Europe, North America, Latin
America & the Caribbean, and Africa (includes corresponding
Graph/Chart) II-9

Table 2: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer- Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America & the
Caribbean, and Africa (includes corresponding Graph/Chart) II-10

Table 3: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung &
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-10

Table 4: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung & Bronchus and Liver Cancers (includes
corresponding Graph/Chart) II-11

Table 5: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung & Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-11

Table 6: Global Cancer Mortality in Women for Select Cancers
(2012): Number of Deaths in Thousands for Breast, Lung &
Bronchus, Colorectal and Liver (includes corresponding
Graph/Chart) II-11

Table 7: World Breast Cancer Statistics: Top 20 Countries
with Highest Breast Cancer Rates (includes corresponding
Graph/Chart) II-12
Cancer Prone Sites based on Age II-12
Targeted Radionuclide Therapy: Gaining Ground in Cancer Treatment II-13
Intra-operative Lymphatic Mapping (ILM): Creating New
Opportunities for Radiopharmaceuticals in Cancer Detection II-13
Emergence of Radioisotope Based Personalized Therapy Bodes
Well for the Market II-13
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance II-14
Widespread Awareness among Practitioners & Patients: The Need
of the Hour II-14
Cardiology: An Important Sector for Radiopharmaceuticals II-14
Expansion of Molecular Imaging Platform is Key to Future Growth II-15
Battling Alzheimer's Disease - A Powerful Market Force II-15
Table 8: Elderly Population (65+ Years) as a Percentage of
the Total Population: 2000 & 2025 (includes corresponding
Graph/Chart) II-16
Growing Demand for PET to Drive up Demand II-17
Opportunities Increasing for Fluorine-Based Myocardial
Perfusion Agents II-17
Innovative PET Biomarkers in the Offing for Oncology II-17
Hypoxia Imaging Presents Opportunities for PET II-18
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for
Growth II-18
Targeted Peptides & Alpha Emitters: The New Frontiers of
Therapeutic Radiopharmaceuticals II-19
International Collaborations Give a Thumbs Up to Drug Development II-19
Key Statistical Data II-20
Table 9: Worldwide Market for 99Mo (2010): Percentage Share
Breakdown of Weekly Demand by Region (includes corresponding
Graph/Chart) II-20

Table 10: Worldwide Market for 99Mo (2010): Percentage Share
Breakdown of Production by Reactor (includes corresponding
Graph/Chart) II-20
Reactors Producing Cobalt 60 & Molybdenum 99 II-21
Table 11: Global Projected Demand for Mo-99 in Emerging and
Mature Markets for the Years 2020 and 2030 (includes
corresponding Graph/Chart) II-21

3. MARKET CHALLENGES II-22
High Costs of Drug Development Piques Manufacturers II-22
Supply Shortages: A Niggling Cause of Concern II-22
Canadian Scientists Discover Means to Address Supply Shortages II-23
Price Sensitivity & Competition from Alternatives Limit Market
Potential II-23
Lack of Dosage Standards for Pediatric Patients Limits
Radiopharmaceutical Efficacy II-24
Unfounded Fears of Radiation Exposure Hinder Growth II-24
Bottlenecks in Developing Markets II-24

4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT II-25
Primer II-25
Lutathera for Neuroendocrine Cancer II-25
Alpharadin for Bone Cancer Treatment II-25
Actimab for Leukemia and Blood Borne Cancers II-25
Lead-212 Alpha Therapy for Metastasized Abdominal Cancers II-26
Lu-177-J591 PSMA Antibody for Prostate Cancer II-26
Indium-111-Pentetreotide for Neuroendocrine Tumors II-26
Yttrium-90 Clivatuzumab for Pancreatic Cancer II-27
CycloSam for Bone Cancer II-27
Phospholid Ether Tumor Targeting II-27

5. IMAGING AGENTS - AN OVERVIEW II-28
A Quick Primer II-28
Growth Drivers II-28
Market Restraints II-29
Significance of Technological Advancements II-29
X-Ray Contrast Media: Giving Way to Emerging Modalities II-29
Medical Reimbursement: A Critical Factor II-30
Market Structure II-30
Select Players by Segment II-30

6. NUCLEAR MEDICINE - AN OVERVIEW II-31
Nuclear Medicine - An Introduction II-31
Growth Drivers in a Nutshell II-31
Market Shifts to Hybrid Imaging II-31

7. PRODUCT OVERVIEW II-33
Radiopharmaceuticals: A Definition II-33
Mechanism of Action II-33
Application of Radiopharmaceuticals II-33
Radioactive Tracers for Diagnostic Imaging II-33
Therapeutics II-33
Research II-34
Sterilization II-34
Classification of Radiopharmaceuticals II-34
Diagnostic Radiopharmaceuticals II-34
Commonly Used Diagnostic Radiopharmaceutical Agents II-34
Major Isotopes and their Diagnostic Applications II-35
Advantages II-36
Classification II-36
Cardiology Diagnostics II-36
Non-cardiology Diagnostics II-36
Molecular Imaging Modalities in Radiopharmaceutical Diagnostics II-36
Planar Imaging II-36
Positron Emission Tomography (PET) II-37
Advantages II-37
Applications of PET II-38
Commonly used Radioisotopes in PET Scans II-38
Major PET Isotopes and their Applications II-38
Single Photon Emission Computed Tomography (SPECT) II-39
Applications of SPECT II-40
Commonly used Radioisotopes in SPECT Scans II-40
Therapeutic Radiopharmaceuticals II-40
Characteristics of Therapeutic Radiopharmaceuticals II-40
Commonly used Therapeutic Agents II-41
Major Isotopes and their Therapeutic Applications II-41
Radiopharmaceuticals for Thyroid Therapy II-41
Radiopharmaceuticals for Cancer Therapy II-42
Radiopharmaceuticals for Neuroendocrine Tumors II-42
Radiopharmaceuticals for Radiosynoviorthesis Therapy II-42
Radiopharmaceuticals for Bone Pain Palliation Therapy II-42
Radiopharmacy: A Key Link in the Distribution Chain II-43
Table 12: US Radiopharmacies Market (2010): Percentage Share
Breakdown of SPECT Doses Sold by Company (includes
corresponding Graph/Chart) II-43

8. PRODUCT INNOVATIONS/INTRODUCTIONS II-44
Positron Launches Advanced PosiRx Pharmacy Automation Systems II-44
BARC Launches Indigenous Radiopharmaceuticals- Powered Scans II-44
Rapidscan Pharma Solutions EU and GE Healthcare Unveil Rapiscan® II-44
Positron Launches PosiRx II-45

9. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST- A PERSPECTIVE
BUILDER II-46
GE Healthcare Enhances Radiopharmaceuticals Product Portfolio II-46
IBA Molecular Obtains Positive Opinion to Market Dopacis in
Europe II-46
BARC Develops Radiopharmaceuticals for Cancer Treatment II-47
Medrad Mounts Intego™ PET Infusion System at UPMC II-47
IBA Molecular Announces the Launch of Cyclone ® 18 Twin II-47
Molecular Insight Develops New Radio-iodinated Molecules II-47
Immunomedics Develops New Antibody for Radio-immunotherapy II-48

10. RECENT INDUSTRY ACTIVITY II-49
Advanced Accelerator Applications Expands Radiopharmaceutical
Manufacturing Network II-49
Advanced Accelerator Applications Inks Partnership Agreement
with Uwrc Spoka Z Ograniczon Odpowiedzialno Ci II-49
Eli Lilly to Purchase Two Radiopharmaceutical Imaging Agents
from Siemens II-49
UPPI Inks Contract with Novation II-50
Dalton Inks Manufacturing Partnership with Clarity
Pharmaceuticals II-50
Lantheus Medical Imaging Extends Agreement with Nordion II-50
Lantheus Medical Imaging and Jubilant HollisterStier Enter
into Agreement II-51
NCM Reveals New Advanced PET Radiopharmaceutical Manufacturing
Center II-51
Turkey Inaugurates First Particle Accelerator II-51
SK Capital and IBA Sign Agreement to Setup IBA Molecular Imaging II-52
Novelos Therapeutics Pockets Cellectar Inc II-52
Southern Research Institute Inks Agreement with Biomedical
Research Foundation II-52
IBA Acquires Minority Stake in PET Net Solutions II-53
Amerinet Inks Group Purchasing Agreement with Positron II-53
Premier Purchasing Partners Awards Supplier Contract to
Lantheus Medical Imaging II-54
MDS Nordion Inks Collaborative Agreement with Avid
Radiopharmaceuticals II-54
Devicor™ Medical Products Acquires Neoprobe® II-54
UHN and CPDC Form Joint Venture II-55
AstraZeneca Inks Licensing Agreement with Neoprobe II-55
Cardinal Health Unveils Molecular Imaging Collaboration Center
in Phoenix Region II-56

11. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER II-57
Covidien Enters into Agreement with IAE POLATOM II-57
Dalat Nuclear Research Institute Inks Agreement with
Probactive Biotech II-57
Principio Wins Licensing Agreement from Johns Hopkins Sidney
Kimmel Comprehensive Cancer Center II-57
Covidien Inks Definitive Agreement with Triad Isotopes II-57
Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals II-58
Lumiphore Inks Agreement with Algeta II-58
IBA Renews Contract with Servicio Andaluz de Salud II-58
Lumiphore and Algeta Ink Partnership Agreement II-59
Positron and Covidien Ink Agreement II-59
PETNET Solutions Expands PET Radiopharmaceutical Network II-60
Triad Isotopes Acquires Radiopharmacy Network of Covidien II-60
Principio Receives Exclusive Technological Development License
from Hopkins Sidney Kimmel Comprehensive Cancer Center II-60
PETNET Solutions Renews Supply Agreement with Paul Strickland
Scanner Centre II-60
IBA Molecular Obtains Marketing Approval for Filtracis
Radiopharmaceutical Kit II-61
DHA Inks MoU with DCD II-61
Algeta Signs Agreement with Bayer II-61
Antisoma Collaborates with Bryan Oncor II-61
Karpov Institute Enters into Collaboration with MDS Nordion II-62
MDS Nordion Establishes Glucotrace Facility II-62
Draximage Inks Agreement with Guerbet II-62
Eczacybathorny-Monrol Collaborates with IBA II-63
Siemens Healthcare Signs Agreement with Calypso Medical II-63
Molecular Insight Signs Agreement with BioMedica Life Sciences II-64
Bayer Schering Signs Agreement with Algeta II-64
IBA Inks Agreement with Aposense II-64
Draxis Receives Approval from Health Canada for Generic Sestamibi II-65
Cyclopharm and Alfred Health Solutions Form Joint Venture II-65
Guerbet Inks Distribution Agreement with Draximage II-65
Ion Beam Applications Collaborates with Eczacibasi-Monrol
Nuclear Products II-66

12. FOCUS ON SELECT PLAYERS II-67
Actinium Pharmaceuticals Inc (US) II-67
Advanced Medical Isotope Corporation (US) II-67
Alseres Pharmaceuticals, Inc (US) II-67
Bayer HealthCare Pharmaceuticals Inc (US) II-68
Bracco Diagnostics, Inc. (US) II-68
Cardinal Health, Inc (US) II-69
Covidien Plc (Ireland) II-69
Eli Lilly and Company (US) II-70
Erigal Limited (UK) II-71
EUSA Pharma (Europe) Ltd. (UK) II-71
GE Healthcare (UK) II-72
IBA Group (Belgium) II-72
Immunomedics, Inc. (US) II-73
Jubilant Life Sciences Limited (India) II-73
Lantheus Medical Imaging Inc (US) II-74
Medi-Radiopharma Ltd (Hungary) II-74
Nordion Inc (Canada) II-75
Peregrine Pharmaceuticals, Inc. (US) II-75
PETNET Solutions Inc (US) II-76
Positron Corporation (US) II-76
Singapore Radiopharmaceuticals Pte Ltd (Singapore) II-77
Triad Isotopes, Inc. (US) II-77

13. GLOBAL MARKET PERSPECTIVE II-78
Table 13: World Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2010 through 2018 (includes corresponding Graph/Chart) II-78

Table 14: World Historic Review for Radiopharmaceuticals by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Middle East and Latin American Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) II-79

Table 15: World 15-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales
for US, Canada, Japan, Europe, Asia-Pacific, Middle East and
Latin American for 2005, 2013 & 2018 (includes corresponding
Graph/Chart) II-80

Table 16: World Recent Past, Current & Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Middle East and Latin
American Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-81

Table 17: World Historic Review for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2004 through 2009 (includes corresponding Graph/Chart) II-82

Table 18: World 15-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific, Middle East and Latin American Markets for 2005,
2013 & 2018 (includes corresponding Graph/Chart) II-83

Table 19: World Recent Past, Current & Future Analysis for
Therapeutic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Middle East and Latin
American Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-84

Table 20: World Historic Review for Therapeutic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Middle East and Latin American Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2004 through 2009 (includes corresponding Graph/Chart) II-85

Table 21: World 15-Year Perspective for Therapeutic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific, Middle East and Latin American Markets for 2005,
2013 & 2018 (includes corresponding Graph/Chart) II-86

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Industry Structure III-1
Production Scenario III-1
Dependence on Imports III-1
DOE's Flawed Isotope Program Causes Shortage Fears in the US III-2
Regulatory Scenario III-2
Thorny Regulations Dampen New Product Development III-2
FDA's Antidote III-3
Overview of Medicare Reimbursements III-3
Medicare Payment Settings for Contrast Agents and
Radiopharmaceuticals III-4
Payments for Radiology Services III-4
Medicare Coverage III-4
Billing and Payment on Medicare Professional Claims III-4
Payment Conditions for Radiology Services III-4
Services Furnished in Hospitals to Inpatients III-5
Services Furnished in Hospitals to Outpatients III-5
Services Furnished in Skilled Nursing Facilities (SNF) III-5
Services Furnished by Rural Health Clinics (RHC) and
Federally Qualified Health Centers (FQHC) III-5
Implications of Reimbursement Changes on Radiology III-5
Radiopharmaceutical Reimbursement in the US: Who's Under the
Umbrella III-6
Diagnostic Radiopharmaceuticals Bundled As Supplies under
Medicare Reimbursements III-6
Concerns over Bundling of Zevalin into Diagnostic
Radiopharmaceuticals Allayed III-6
Improved Reimbursement for Therapeutic Radiopharmaceuticals III-7
Market Overview III-7
Sanguine Growth On Cards III-7
Expanding Diagnostic Applications Will Stimulate Future Growth III-7
Nuclear Cardiology Products Drive Up Diagnostic
Radiopharmaceuticals Market III-7
Cardiovascular Imaging To Lead Volume Growth III-8
Cardiolite Loses Market Share to Generics III-8
Table 22: The US Diagnostic Radiopharmaceutical Agents
Market (2012): Percentage Share Breakdown of Procedure
Volume by Imaging Procedure - SPECT and PET (includes
corresponding Graph/Chart) III-9

Table 23: US Market for Diagnostic Radiopharmaceuticals
Agents (2012): Percentage Share Breakdown of Value Sales
for Cardiology and Non-Cardiology Applications (includes
corresponding Graph/Chart) III-9

Table 24: US Market for Cardiology Diagnostic
Radiopharmaceuticals (2010): Percentage Share Breakdown of
SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume
by Imaging Agent - Cardiolite, Myoview, Thallium, and
Sestamibi (includes corresponding Graph/Chart) III-10
New Oncology, Neurology Agents to Boost Diagnostic
Radiopharmaceuticals Market III-10
Table 25: US Market for Non-Cardiology Diagnostic
Radiopharmaceuticals Agents (2012): Percentage Share
Breakdown of Value Sales for Oncology and Non-Oncology
Applications (includes corresponding Graph/Chart) III-11
Installed Base of SPECT Scanners III-11
Table 26: Diagnostic Radiopharmaceutical Market in North
America: Installed Base for SPECT and SPECT/CT Scanners in
Units for Years 2006, 2008, 2010, 2012 & 2014 (includes
corresponding Graph/Chart) III-11
Installed Pet Scanners in US III-12
US FDG Market III-12
Table 27: US FDG Market (2012): Percentage Share Breakdown
of Procedure Volume by Procedure Type - Oncology,
Neurology and Cardiology (includes corresponding
Graph/Chart) III-12
Focused R&D Efforts will Fuel Therapeutic
Radiopharmaceuticals Market III-12
Market Share Statistics III-13
Table 28: US Market for Diagnostic Radiopharmaceuticals
Agents (2011): Percentage Market Share Breakdown for
Leading Players (includes corresponding Graph/Chart) III-13

Table 29: US Market for Therapeutic Radiopharmaceuticals
(2012): Percentage Share Breakdown of Value Sales by Key
Radiotherapeutics - Bone Palliation, Non-Hodgkin's
Lymphoma, Hyperthyroidism /Thyroid Cancer and Others
(includes corresponding Graph/Chart) III-13

Table 30: US Market for Therapeutic Radiopharmaceutical
Agents (2010): Percentage Market Share Breakdown of Leading
Players (includes corresponding Graph/Chart) III-14

Table 31: US Market for Radiopharmaceutical Bone Palliation
Procedures (2012): Percentage Share Breakdown by Key
Radiotherapeutics - Metastron, Quadramet and Sr-89
(includes corresponding Graph/Chart) III-14

Table 32: Radiopharmacy Market in the US (2012): Percentage
Breakdown of Revenues Generated by General Radiopharmacies
and FDG Radiopharmacies (includes corresponding
Graph/Chart) III-14
Product Launches III-15
Strategic Corporate Developments III-15
Select Players III-19
B.Market Analytics III-28
Table 33: US Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-28

Table 34: US Historic Review for Radiopharmaceuticals by
Segment - Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-29

Table 35: US 15-Year Perspective for Radiopharmaceuticals by
Segment - Percentage Breakdown of Value Sales for Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets for Years 2005, 2013 & 2018 (includes corresponding
Graph/Chart) III-30

2. CANADA III-31
A.Market Analysis III-31
Outlook III-31
Canadian Scientists Lead the Discovery of Remedy for Supply
Shortages III-31
An Overview of Medical Imaging Market III-31
Regulatory and Legal Restrictions III-32
Strategic Corporate Developments III-32
Select Players III-33
B.Market Analytics III-35
Table 36: Canadian Recent Past, Current & Future Analysis
for Radiopharmaceuticals by Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart)

To order this report:
Medical_Imaging Industry: Global Radiopharmaceuticals Industry

Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker